Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Not applicableLooking for participantsNCT05122806What this trial is testingAnalysis of Biological Characteristics of Advanced ALK-rearranged NSCLCWho this might be right forNon-small Cell Lung CancerALK Gene Rearrangement Positive Groupe Francais De Pneumo-Cancerologie 100
Not applicableLooking for participantsNCT07374614What this trial is testingIruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibWho this might be right forNon-Small Cell Lung CancerALKIruplinalkib+3 more Peking University Shenzhen Hospital 20
Not applicableAvailableNCT06834074What this trial is testingExpanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid TumorsWho this might be right forNon Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC) Nuvalent Inc.
Not applicableStudy completedNCT06339554What this trial is testingAlectinib-induced Endocrine ToxicityWho this might be right forNSCLC Stage IV Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Early research (Phase 1)UnknownNCT03130881What this trial is testingPhase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.Who this might be right forNon-Small Cell Lung Cancer Beijing Pearl Biotechnology Limited Liability Company 60
Not applicableActive Not RecruitingNCT07556549What this trial is testingLearn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCWho this might be right forNon-Small Cell Lung Cancer ALK-positive Pfizer 50
Not applicableNot Yet RecruitingNCT07191405What this trial is testingClinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid TumorsWho this might be right forImmunotherapyChemotherapy Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Not applicableUnknownNCT04317651What this trial is testingCrizotinib in ALK Rearranged Non-small-cell Lung CancerWho this might be right forNon Small Cell Lung CancerAdvanced CancerMetastatic Cancer Fondazione Ricerca Traslazionale 500
Testing effectiveness (Phase 2)UnknownNCT05869162What this trial is testingPhase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKIWho this might be right forNon-small-cell Lung Carcinoma Shouyao Holdings (Beijing) Co. LTD 153
Early research (Phase 1)Ended earlyNCT03087448What this trial is testingCeritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer University of California, San Francisco 9
Not applicableEnded earlyNCT02228421What this trial is testingStudy to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC PatientsWho this might be right forNon-small Cell Lung Cancer Metastatic PeriPharm 29
Testing effectiveness (Phase 2)Study completedNCT04111705What this trial is testingLorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Metastatic Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Study completedNCT03607188What this trial is testingStudy of Alkotinib in Patients With Advanced Non Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableActive Not RecruitingNCT04764188What this trial is testingAn Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With AlectinibWho this might be right forNSCLC Hoffmann-La Roche 800
Testing effectiveness (Phase 2)Looking for participantsNCT07491497What this trial is testingTRI-611 in ALK-Positive NSCLCWho this might be right forALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer TRIANA Biomedicines, Inc. 160
Not applicableNot Yet RecruitingNCT07045610What this trial is testingPrimary Resistance Mechanisms of ALK TKIsWho this might be right forALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS National Taiwan University Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010What this trial is testingAlectinib in Neo-adjuvant Treatment of Stage III NSCLCWho this might be right forNon Small Cell Lung Cancer Gruppo Oncologico Italiano di Ricerca Clinica 33
Large-scale testing (Phase 3)Study completedNCT02604342What this trial is testingAlectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibWho this might be right forNon-small Cell Lung Cancer Hoffmann-La Roche 119
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599What this trial is testingSY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCWho this might be right forNon-small Cell Lung Cancer Shouyao Holdings (Beijing) Co. LTD 255